新型褪黑素受体激动剂Neu-240改善帕金森模型小鼠运动行为损伤

A Novel Melatonin Agonist Neu-240 Ameliorates Behavioral Deficits in a MPTP Mouse Model of Parkinson's Disease

目的:评估一种新型褪黑素受体激动剂Neu-240对MPTP(1-甲基-4-苯基-1,2,3,6-四氢吡啶)诱导帕金森模型小鼠运动功能损伤的潜在保护作用。方法:C57BL/6小鼠每天腹腔注射一次MPTP(30 mg/kg),连续注射5 d,建立PD小鼠模型;Neu-240(0.1或3 mg/kg)腹腔注射开始于MPTP注射的第1天,1次/d,连续17 d。分别在MPTP注射后第14、15及17天进行行为学检测,包括开放场测试、爬杆测试及悬挂测试。结果:在开放场测试与悬挂测试中,Neu-240能够分别显著性改善MPTP诱导的活动距离与运动评分水平的降低;在爬杆测试中,Neu-240对MPTP诱导的转向时间和总时间无显著性影响,仅表现为改善的趋势。结论:新型褪黑素受体激动剂Neu-240能部分改善帕金森模型小鼠运动功能损伤。

Objective：To assess the potential protective effects of the novel melatonin agonist Neu-240 in the MPTP mouse model of Parkinson＇s disease.Method：Mice received daily injections of saline or MPTP（30 mg/kg） once per day for five consecutive days to induce Parkinsonism. Vehicle or Neu-240（0.1 or 3 mg/kg） once per day was administered（i.p.） once per day for 17 days, starting on the first day of MPTP injections. Open field test, pole test and traction test were conducted on day 14, 15 and 17 after the first injections of MPTP, respectively.Result：Neu-240 at 3 mg/kg improved behavioral impairment induced by MPTP in the open field test and traction test but not in the pole test. Neu-240 at 0.1 mg/kg was effective only in the open field test. Conclusion：The novel melatonin agonist Neu-240 exerts partial protective effects in the MPTP mouse model of Parkinson＇s disease.